STRASBOURG, France, April 12 /PRNewswire-FirstCall/ -- Transgene S.A. - Transgene announces its cash position and net cash expenditures for the 3 months ending March 31, 2006 (unaudited figures, IAS/IFRS).
Cash, cash equivalents and short term investments totaled EUR 21.4 million at March 31, 2006. The net cash expenditures amounted to EUR 5.3 million for the first quarter of 2006, excluding warrant exercise proceeds, compared to EUR 4.6 million in the first quarter of 2005, in line with the net cash expenditures to the order of EUR 21 million expected for the fiscal year 2006.
Proceeds amounting to EUR 0.2 million were raised in the first quarter of 2006 through the exercise of warrants issued as part of the July 2005 capital increase. An additional EUR 18.5 million could be raised by July 2006 if all the remaining warrants are exercised (warrant exercise price: EUR 8.05).
About Transgene :
Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has three compounds in Phase II trials and one compound in Phase I studies. Transgene has bio-manufacturing production capacities for viral-based vectors and technologies available for out-licensing. For further information about Transgene, please visit www.transgene.fr
Press Contacts: Transgene Capital MS&L Image 7 Philippe Poncet Shaun Brown Estelle Guillot-Tantay +33-3-88-27-91-21 Mary Clark Tiphaine Hecketsweiler +44-(0)20-7307-5330 +33-1-53-70-74-93
Transgene S.A.CONTACT: Transgene: Philippe Poncet, +33-3-88-27-91-21. Capital MS&L:Shaun Brown, Mary Clark, +44-(0)20-7307-5330. Image 7: EstelleGuillot-Tantay, Tiphaine Hecketsweiler, +33-1-53-70-74-93
